Shandong Buchang Pharmaceuticals Co (SHSE:603858) 3-Year EBITDA Growth Rate : -27.90% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shandong Buchang Pharmaceuticals Co 3-Year EBITDA Growth Rate?

Shandong Buchang Pharmaceuticals Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.22.

During the past 3 years, the average EBITDA Per Share Growth Rate was -27.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shandong Buchang Pharmaceuticals Co was 41.20% per year. The lowest was -27.90% per year. And the median was 2.05% per year.

Competitive Comparison of Shandong Buchang Pharmaceuticals Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Buchang Pharmaceuticals Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Buchang Pharmaceuticals Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Buchang Pharmaceuticals Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shandong Buchang Pharmaceuticals Co's 3-Year EBITDA Growth Rate falls into.

Shandong Buchang Pharmaceuticals Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Shandong Buchang Pharmaceuticals Co (SHSE:603858) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Shandong Buchang Pharmaceuticals Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shandong Buchang Pharmaceuticals Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Buchang Pharmaceuticals Co (SHSE:603858) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Buchang Pharmaceuticals Co Ltd (SHSE:603858) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

No. 369, Zhonghua West Road, Shandong Province, Heze, CHN, 274000

Website

http://www.buchang.com

Shandong Buchang Pharmaceuticals Co Ltd is a pharmaceuticals company engaged in drug manufacturing. It specializes in the research and development, production and sale of Traditional Chinese patent medicines, supplemented by fields such as hi-tech industry and health industry. The company offers drugs for cardiac and cerebral vascular disease, diabetes, urinary and digestive disease, respiratory disease, gynecological disease and others. Geographically, the company holds its production bases in Shandong, Shaanxi, Hebei and Northeast China, with its marketing network spreading all over the major provinces of China.

Shandong Buchang Pharmaceuticals Co (SHSE:603858) Headlines

No Headlines